Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMDN12L)

Drug Name
2,6-Dihydroanthra/1,9-Cd/Pyrazol-6-One Drug Info
Synonyms
Anthra[1,9-cd]pyrazol-6(2H)-one; 129-56-6; 1,9-Pyrazoloanthrone; SP600125; Pyrazolanthrone; Dibenzo[cd,g]indazol-6(2H)-one; Pyrazoleanthrone; SP 600125; Anthra-1,9-pyrazol-6-none; SP-600125; CI 70300; 2H-Dibenzo[cd,g]indazol-6-one; JNK Inhibitor II; SAPK Inhibitor II; NSC 75890; UNII-1TW30Y2766; ANTHRA(1,9-cd)PYRAZOL-6(2H)-ONE; EINECS 204-955-6; 2,6-DIHYDROANTHRA/1,9-CD/PYRAZOL-6-ONE; BRN 0746890; CHEMBL7064; MLS002693964; CHEBI:90695; ACPOUJIDANTYHO-UHFFFAOYSA-N; 1TW30Y2766
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1] , [2]
Cross-matching ID
PubChem CID
8515
ChEBI ID
CHEBI:90695
CAS Number
CAS 129-56-6
TTD Drug ID
DMDN12L

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Patented Agent(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Stress-activated protein kinase JNK3 (JNK3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID25991433-Compound-A1 DM89LF0 N. A. N. A. Patented [5]
PMID25991433-Compound-F2 DM37VIQ N. A. N. A. Patented [5]
7-azaindole derivative 1 DMQL5B7 N. A. N. A. Patented [5]
7-azaindole derivative 5 DMV3H98 N. A. N. A. Patented [5]
PMID25991433-Compound-P6 DMNDVC9 N. A. N. A. Patented [5]
PMID25991433-Compound-J3 DM17P3F N. A. N. A. Patented [5]
PMID25991433-Compound-P1 DMD8AX6 N. A. N. A. Patented [5]
PMID25991433-Compound-O3 DMVOWS5 N. A. N. A. Patented [5]
PMID25991433-Compound-J2 DMZSOCK N. A. N. A. Patented [5]
7-azaindole derivative 3 DMQ7BV4 N. A. N. A. Patented [5]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Stress-activated protein kinase JNK1 (JNK1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
NKP-1339 DM5AWK1 Solid tumour/cancer 2A00-2F9Z Phase 1 [6]
PMID25991433-Compound-A1 DM89LF0 N. A. N. A. Patented [5]
PMID25991433-Compound-F2 DM37VIQ N. A. N. A. Patented [5]
7-azaindole derivative 1 DMQL5B7 N. A. N. A. Patented [5]
7-azaindole derivative 5 DMV3H98 N. A. N. A. Patented [5]
PMID25991433-Compound-P6 DMNDVC9 N. A. N. A. Patented [5]
PMID25991433-Compound-J3 DM17P3F N. A. N. A. Patented [5]
PMID25991433-Compound-P1 DMD8AX6 N. A. N. A. Patented [5]
PMID25991433-Compound-O3 DMVOWS5 N. A. N. A. Patented [5]
PMID25991433-Compound-L1 DM2135Y N. A. N. A. Patented [5]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Stress-activated protein kinase JNK2 (JNK2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID25991433-Compound-A1 DM89LF0 N. A. N. A. Patented [5]
PMID25991433-Compound-F2 DM37VIQ N. A. N. A. Patented [5]
7-azaindole derivative 1 DMQL5B7 N. A. N. A. Patented [5]
7-azaindole derivative 5 DMV3H98 N. A. N. A. Patented [5]
PMID25991433-Compound-P6 DMNDVC9 N. A. N. A. Patented [5]
PMID25991433-Compound-J3 DM17P3F N. A. N. A. Patented [5]
PMID25991433-Compound-P1 DMD8AX6 N. A. N. A. Patented [5]
PMID25991433-Compound-O3 DMVOWS5 N. A. N. A. Patented [5]
PMID25991433-Compound-J2 DMZSOCK N. A. N. A. Patented [5]
7-azaindole derivative 3 DMQ7BV4 N. A. N. A. Patented [5]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Dual specificity protein kinase TTK (MPS1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
BOS172722 DMU790L Solid tumour/cancer 2A00-2F9Z Phase 1 [7]
BAY1161909 DMUK6YM Solid tumour/cancer 2A00-2F9Z Phase 1 [8]
CFI-402257 DMH701Q Solid tumour/cancer 2A00-2F9Z Phase 1 [9]
Tricyclic isoxazoloquinazoline derivative 2 DMH4TY1 N. A. N. A. Patented [10]
Tricyclic isoxazoloquinazoline derivative 4 DM8VIM4 N. A. N. A. Patented [10]
Tricyclic isoxazoloquinazoline derivative 3 DML2PWF N. A. N. A. Patented [10]
GNE-7915 DMYWM56 Discovery agent N.A. Investigative [11]
⏷ Show the Full List of 7 Drug(s)
Drug(s) Targeting Jun N terminal kinase (JNK)
Drug Name Drug ID Indication ICD 11 Highest Status REF
AM-111 DM4E9PK Neurological disorder 6B60 Phase 3 [12]
BGP-15 DMYDM68 Type-2 diabetes 5A11 Phase 2 [13]
CC-401 DMPMO6G Solid tumour/cancer 2A00-2F9Z Phase 2 [14]
CC-930 DMHVEGJ Discoid lupus erythematosus EB51.0 Phase 2 [15]
PMID25991433-Compound-Q1 DMEMSB2 N. A. N. A. Patented [5]
PMID25991433-Compound-O1 DMH073T N. A. N. A. Patented [5]
⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dual specificity protein kinase TTK (MPS1) TTP7EGM TTK_HUMAN Inhibitor [1]
Jun N terminal kinase (JNK) TTR2TXZ MK08_HUMAN; MK09_HUMAN; MK10_HUMAN Inhibitor [3]
Stress-activated protein kinase JNK1 (JNK1) TT0K6EO MK08_HUMAN Inhibitor [1]
Stress-activated protein kinase JNK2 (JNK2) TTHS0U8 MK09_HUMAN Inhibitor [4]
Stress-activated protein kinase JNK3 (JNK3) TT056SO MK10_HUMAN Inhibitor [1]

References

1 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5273).
3 c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest. 2001 Jul;108(1):73-81.
4 Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5.
5 c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1496).
7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8 National Cancer Institute Drug Dictionary (drug id 761238).
9 Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer. Proc Natl Acad Sci U S A. 2017 Mar 21;114(12):3127-3132.
10 Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48.
11 Discovery of highly potent, selective, and brain-penetrant aminopyrazole leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. J Med Chem. 2014 Feb 13;57(3):921-36.
12 The JNK inhibitor XG-102 protects against TNBS-induced colitis.PLoS One.2012;7(3):e30985.
13 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
14 Signal integration by JNK and p38 MAPK pathways in cancer development.Nat Rev Cancer.2009 Aug;9(8):537-49.
15 In vitro metabolism of a novel JNK inhibitor tanzisertib: interspecies differences in oxido-reduction and characterization of enzymes involved in metabolism. Xenobiotica. 2015;45(6):465-80.